HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Recalls Infant Acetaminophen Liquid With Blank Dosing Syringe

This article was originally published in The Tan Sheet

Executive Summary

The private labeler initiated a retail-level nationwide recall of acetaminophen infant suspension liquid, 160 mg/5 mL, sold in 2- and 4-ounce bottles with syringes because of the “remote potential that a small number of packages might contain an oral dosing syringe without dose markings.”

You may also be interested in...

CHPA Petitions For Acetaminophen Under-2 Dose Labeling

CHPA urges FDA not to wait until it publishes the final internal analgesics, antipyretic and anti-rheumatic monograph before allowing manufacturers to label acetaminophen products with dosing information for children 6 months to 2 years old. In a citizen petition, the trade group proposes FDA publish a statement of enforcement policy expressly permitting the use of a standardized age- and weigh-based dosing chart.

McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem

McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.

Perrigo Applies Crime Scene Investigation Model To Improve Quality Control

Perrigo quality control managers emphasize immediate investigations of low-risk incidents and forward-looking remediation in the firm’s new corrective and preventive actions strategy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts